EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer

Fatemeh Khojasteh Poor, Mona Keivan, Mohammad Ramazii, Farhoodeh Ghaedrahmati, Amir Anbiyaiee, Samira Panahandeh, Seyed Esmaeil Khoshnam, Maryam Farzaneh

Breast Disease · 18.06.2021 · 40 (2) · 51-62

DOI: 10.3233/bd-201063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Breast Disease, erschienen am 18.06.2021. Verfasst von Fatemeh Khojasteh Poor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 168 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most common cancer and the prevalent type of malignancy among women. Multiple risk factors, including genetic changes, biological age, dense breast tissue, and obesity are associated with BC. The mitogen-activated protein kinases (MAPK) signaling pathway has a pivotal role in regulating biological functions such as cell proliferation, differentiation, apoptosis, and survival. It has become evident that the MAPK pathway is associated with tumorigenesis and may promote breast cancer development. The MAPK/RAS/RAF cascade is closely associated with breast cancer. RAS signaling can enhance BC cell growth and progression. B-Raf is an important kinase and a potent RAF isoform involved in breast tumor initiation and differentiation. Depending on the reasons for cancer, there are different strategies for treatment of women with BC. Till now, several FDA-approved treatments have been investigated that inhibit the MAPK pathway and reduce metastatic progression in breast cancer. The most common breast cancer drugs that regulate or inhibit the MAPK pathway may include Farnesyltransferase inhibitors (FTIs), Sorafenib, Vemurafenib, PLX8394, Dabrafenib, Ulixertinib, Simvastatin, Alisertib, and Teriflunomide. In this review, we will discuss the roles of the MAPK/RAS/RAF/MEK/ERK pathway in BC and summarize the FDA-approved prescription drugs that target the MAPK signaling pathway in women with BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticFemaleHumansMitogen-Activated Protein KinasesPrescription DrugsSignal TransductionUnited StatesUnited States Food and Drug Administration

Stichwörter der Autor:innen

Breast cancerFDA-approved drugsMAPK pathwayMEK/ERKRAS/RAF

Substanzen

Prescription DrugsMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Kerman University of Medical Sciences, University of Kerman, Kerman, Iran.
  • Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Department of Surgery, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Zitieren

APA

Khojasteh Poor, F., Keivan, M., Ramazii, M., Ghaedrahmati, F., Anbiyaiee, A., Panahandeh, S., Khoshnam, S. E., & Farzaneh, M. (2021). Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Disease, 40(2), 51-62. https://doi.org/10.3233/bd-201063

Vancouver

Khojasteh Poor F, Keivan M, Ramazii M, Ghaedrahmati F, Anbiyaiee A, Panahandeh S, et al. Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Disease. 2021;40(2):51-62. doi:10.3233/bd-201063

BibTeX
@article{KhojastehPoor2021,
  author = {Khojasteh Poor, Fatemeh and Keivan, Mona and Ramazii, Mohammad and Ghaedrahmati, Farhoodeh and Anbiyaiee, Amir and Panahandeh, Samira and Khoshnam, Seyed Esmaeil and Farzaneh, Maryam},
  title = {Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer},
  journal = {Breast Disease},
  year = {2021},
  volume = {40},
  number = {2},
  pages = {51--62},
  doi = {10.3233/bd-201063}
}
Kostenlos starten →